ADPT
Companies
NASDAQ
Adaptive Biotechnologies Corporation
Health Care
$10.47
+$4.48 (+74.65%)
Price Chart
Overview
About ADPT
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Market Cap
$532.0M
Volume
15.5M
Avg. Volume
26.9M
P/E Ratio
-9.957446
Dividend Yield
0.00%
Employees
770.0
Company Information
Risk & Correlation Analysis
Market Correlation
2.02
High Correlation
Volatility
High (0.82)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ADPT shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$532.0M
Volume15.5M
P/E Ratio-9.96
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 2, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025